GlassScriptPhysician profile
Edward T Cullom
NPI 1710997135
$10,365.49
in general payments reported to CMS, 2019-2025
31 companies · $1,452 in 2025
The $1,452 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,227 · 2020: $2,364 · 2021: $1,457 · 2022: $2,398 · 2023: $366 · 2024: $1,102 · 2025: $1,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,061 · Travel and Lodging: $858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,061.28 |
| Travel and Lodging | $857.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,441.06 | 2019-2025 | Eterna, Proclaim |
| Carl Zeiss Meditec, INC. | $1,984.77 | 2020 | |
| Si-Bone, INC. | $1,768.39 | 2020-2024 | |
| Spineology INC. | $877.28 | 2025 | |
| Medtronic USA, INC. | $765.78 | 2019-2020 | |
| Medtronic, INC. | $562.72 | 2021-2025 | Intellis Adaptivestim, Mazor X System, Accurian |
| Lundbeck LLC | $244.12 | 2023-2024 | Vyepti, Rexulti |
| Abbvie INC. | $242.43 | 2024-2025 | |
| Nevro Corp. | $157.55 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $139.45 | 2023-2025 | Nuplazid |
| Providence Medical Technology, INC. | $123.16 | 2021-2023 | |
| Spinal Elements, INC. | $116.55 | 2023-2024 | |
| 4web, INC. | $102.00 | 2022 | |
| Ucb, INC. | $99.19 | 2024-2025 | Briviact, Nayzilam |
| Lilly USA, LLC | $92.49 | 2024-2025 | Reyvow, Emgality, Kisunla |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $90.59 | 2024 | Ongentys, Rytary |
| Boston Scientific Corporation | $87.57 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Sk Life Science, INC. | $73.34 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $56.94 | 2024-2025 | Xeomin |
| Csl Behring | $53.65 | 2024 | Hizentra |
| Acorda Therapeutics, INC | $48.99 | 2023-2024 | Inbrija |
| Ani Pharmaceuticals, INC. | $36.59 | 2024 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $34.06 | 2025 | Ultomiris |
| Biogen, INC. | $29.02 | 2025 | Leqembi |
| Eisai INC. | $28.98 | 2024 | |
| Sumitomo Pharma America, INC. | $22.96 | 2023 | Aptiom |
| Xeris Pharmaceuticals, INC. | $21.71 | 2024 | Keveyis |
| Depuy Synthes Sales INC. | $17.45 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $16.04 | 2025 | Exparel |
| Otsuka America Pharmaceutical, INC. | $15.54 | 2024 | Nuedexta |
| Sanara Medtech INC. | $15.12 | 2023 | Celleraterx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Cullom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.